MRUS
Merus N.V.96.92
+0.10+0.1%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.35BP/E (TTM)
-Basic EPS (TTM)
-5.28Dividend Yield
0%Recent Filings
8-K
Genmab completes Merus buyout
Genmab completed its $97.00 per share cash takeover of Merus on December 29, 2025, via tender offer and back-end merger, securing 97.39% of shares after 94.2% tendered initially. Trading halted on Nasdaq that evening, with delisting and SEC deregistration to follow. All shares cancelled; no shares remain outstanding. Directors Maxine Gowen and Anand Mehra resigned.
8-K
Genmab completes Merus takeover
Genmab's subsidiary completed its tender offer for Merus on December 12, 2025, securing 94.2% of shares for $97.00 each in cash, totaling $6.9 billion. Control shifted, triggering board overhaul: prior directors and executives like CEO Lundberg exited, while Jan van de Winkel took CEO reins alongside new Genmab appointees. Subsequent offering runs through December 29. Acquisition locked in.
8-K
Shareholders back Genmab takeover
Merus shareholders overwhelmingly approved back-end merger transactions and Genmab designees to its board at the December 9, 2025 EGM, clearing a key hurdle for Genmab's $97.00-per-share cash tender offer expiring December 11. Proposal 1a passed with 53.7M for votes. Offer advances to subsequent period if conditions met. Directors join post-closing.
10-Q
Q3 FY2025 results
Merus posted Q3 revenue of $12.2M, edging up 3% y/y from $11.8M (derived), fueled by a $3.0M Gilead milestone while Lilly revenue faded. R&D expenses jumped 27% y/y to $80.0M (derived), driven by petosemtamab trials at $49.9M, yielding a $96.5M operating loss, 34% wider y/y, versus $72.2M net loss narrowed by interest income. Cash swelled to $367.5M, bolstered by $326M equity raise; no debt. Genmab tender offer at $97/share, expiring Dec 11, awaits 80% tender and HSR clearance. Petosemtamab phase 3s enrolling fast. Deal failure risks capital needs.
8-K
Genmab tenders $97/share for Merus
Merus signed a transaction agreement on September 29, 2025, for Genmab's subsidiary to tender offer all common shares at $97.00 cash per share. The deal requires 80% tender (reducible to 75%), EGM approval, and antitrust clearances, targeting early Q1 2026 close before April 29 outside date. Merus board recommends acceptance. Regulatory hurdles loom.
ABCL
AbCellera Biologics Inc.
3.46-0.05
AGEN
Agenus Inc.
3.72+0.01
BNTX
BioNTech SE
92.23-1.52
CHRS
Coherus Oncology, Inc.
1.39+0.00
IMRX
Immuneering Corporation
5.74-0.04
IMTX
Immatics N.V.
10.09+0.11
LVTX
LAVA Therapeutics N.V.
1.74+0.00
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MRSN
Mersana Therapeutics, Inc.
29.05+0.46